Comment from Juliet Stanton
AnonymousSupportIndividual
Summary: A patient with treatment-resistant depression argues that the FDA should evaluate IV ketamine for drug repurposing to treat severe depressive illness. The commenter shares their personal success with the treatment and emphasizes that FDA approval would help overcome insurance barriers and make the life-saving treatment more affordable and accessible to others.
See attached. (I kept encountering errors when entering my comment here.)